Managing the Drug Discovery Process, Second Edition thoroughly examines the current state of pharmaceutical research and development by providing experienced perspectives on biomedical research, drug hunting and innovation, including the requisite educational paths that enable students to chart a career path in this field. The book also considers the interplay of stakeholders, consumers, and drug firms with respect to a myriad of factors. Since drug research can be a high-risk, high-payoff industry, it is important to students and researchers to understand how to effectively and strategically manage both their careers and the drug discovery process.
This new edition takes a closer look at the challenges and opportunities for new medicines and examines not only the current research milieu that will deliver novel therapies, but also how the latest discoveries can be deployed to ensure a robust healthcare and pharmacoeconomic future. All chapters have been revised and expanded with new discussions on remarkable advances including CRISPR and the latest gene therapies, RNA-based technologies being deployed as vaccines as well as therapeutics, checkpoint inhibitors and CAR-T approaches that cure cancer, diagnostics and medical devices, entrepreneurship, and AI. Written in an engaging manner and including memorable insights, this book is aimed at anyone interested in helping to save countless more lives through science. A valuable and compelling resource, this is a must-read for all students, educators, practitioners, and researchers at large—indeed, anyone who touches this critical sphere of global impact—in and around academia and the biotechnology/pharmaceutical industry.
1. Chapter 3 Introduction: Preprofessional education - p. 67 2. Chapter 4 Two-year certification and degree programs - p. 75 3. Chapter 5 Four-year undergraduate degree programs - p. 87 4. Chapter 6 The big decision - p. 113 5. Chapter 7 Graduate and postgraduate education at a crossroads - p. 125 6. Chapter 8 Master's degree programs - p. 157 7. Chapter 9 Doctoral and professional programs - p. 169 8. Chapter 10 The big leap - p. 197 9. Chapter 11 Drug discovery: Standing on the shoulders of giants - p. 207 10. Keywords - p. 207 11. 11.1 Sampling various important and instructive topics - p. 207 12. 11.2 Getting the basics right: Fundamentals of good science, including reproducibility - p. 210 13. 11.3 Chemical synthesis technologies - p. 211 14. 11.4 Chemical diversity - p. 216 15. 11.5 Drug delivery - p. 228 16. 11.6 Mitochondria and organelles - p. 228 17. 11.7 Genetics, genomics, proteomics, and more - p. 229 18. 11.8 Chemical biology and its applications - p. 233 19. 11.9 Antibodies and macromolecules - p. 238 20. 11.10 Computational technologies - p. 242 21. 11.11 Easy to forget - p. 254 22. 11.12 Alzheimer's disease and other neurodegenerative conditions - p. 256 23. 11.13 Target classes and key biological mechanisms - p. 259 24. 11.14 SARS-CoV-2 as case study in new and old technologies - p. 291 25. 11.15 Afterword - p. 291 26. References - p. 296 27. Chapter 12 Drug discovery processes: When and where the rubber meets the road - p. 339 28. Keywords - p. 339 29. 12.1 Introduction - p. 339 30. 12.2 Target identification and validation - p. 349 31. 12.3 Hit identification - p. 356 32. 12.4 Antibody-based drug discovery - p. 371 33. 12.5 Nucleic acid-based discovery - p. 378 34. 12.6 Hit-to-lead and lead optimization phases of drug discovery - p. 387 35. 12.7 Candidate selection - p. 400 36. 12.8 Afterword - p. 404 37. References - p. 404 38. Chapter 13 Drug discovery: Chaos can be your friend or your enemy - p. 417 39. Keywords - p. 417 40. 13.1 Introduction to selected aspects of biotechnology and pharmaceutical R&D - p. 417 41. 13.2 Major issues including attrition, cost, financing, ROI, and timelines - p. 434 42. 13.3 Champions, teams, and project management - p. 465 43. 13.4 Recruiting, developing, compensating, and retaining valuable human resources - p. 471 44. 13.5 Multiple sites and outsourcing - p. 476 45. 13.6 Comparing and contrasting centers and sectors of innovation - p. 479 46. 13.7 BD including IP - p. 484 47. 13.8 Afterword - p. 488 48. References - p. 491 49. Chapter 14 Research and discovery: Essential partners but just a start - p. 513 50. Chapter 15 Turning a potent agent—A chemical “drug”—into a registered product - p. 531 51. Chapter 16 Chemical development: Synthetic studies and engineering including aspects of batch production and continuous processing - p. 539 52. Chapter 17 Chemical development: Analytical studies - p. 553 53. Chapter 18 FDA path and process: Sponsor’s regulatory tasks for drug approval - p. 561 54. Chapter 19 Development of biological and other healthcare products - p. 575 55. Chapter 20 Epilogue - p. 619 56. Index - p. 633
Managing the Drug Discovery Process, Second Edition thoroughly examines the current state of pharmaceutical research and development by providing experienced perspectives on biomedical research, drug hunting and innovation, including the requisite educational paths that enable students to chart a career path in this field. The book also considers the interplay of stakeholders, consumers, and drug firms with respect to a myriad of factors. Since drug research can be a high-risk, high-payoff industry, it is important to students and researchers to understand how to effectively and strategically manage both their careers and the drug discovery process.
This new edition takes a closer look at the challenges and opportunities for new medicines and examines not only the current research milieu that will deliver novel therapies, but also how the latest discoveries can be deployed to ensure a robust healthcare and pharmacoeconomic future. All chapters have been revised and expanded with new discussions on remarkable advances including CRISPR and the latest gene therapies, RNA-based technologies being deployed as vaccines as well as therapeutics, checkpoint inhibitors and CAR-T approaches that cure cancer, diagnostics and medical devices, entrepreneurship, and AI. Written in an engaging manner and including memorable insights, this book is aimed at anyone interested in helping to save countless more lives through science. A valuable and compelling resource, this is a must-read for all students, educators, practitioners, and researchers at large—indeed, anyone who touches this critical sphere of global impact—in and around academia and the biotechnology/pharmaceutical industry.
1. Chapter 3 Introduction: Preprofessional education - p. 67 2. Chapter 4 Two-year certification and degree programs - p. 75 3. Chapter 5 Four-year undergraduate degree programs - p. 87 4. Chapter 6 The big decision - p. 113 5. Chapter 7 Graduate and postgraduate education at a crossroads - p. 125 6. Chapter 8 Master's degree programs - p. 157 7. Chapter 9 Doctoral and professional programs - p. 169 8. Chapter 10 The big leap - p. 197 9. Chapter 11 Drug discovery: Standing on the shoulders of giants - p. 207 10. Keywords - p. 207 11. 11.1 Sampling various important and instructive topics - p. 207 12. 11.2 Getting the basics right: Fundamentals of good science, including reproducibility - p. 210 13. 11.3 Chemical synthesis technologies - p. 211 14. 11.4 Chemical diversity - p. 216 15. 11.5 Drug delivery - p. 228 16. 11.6 Mitochondria and organelles - p. 228 17. 11.7 Genetics, genomics, proteomics, and more - p. 229 18. 11.8 Chemical biology and its applications - p. 233 19. 11.9 Antibodies and macromolecules - p. 238 20. 11.10 Computational technologies - p. 242 21. 11.11 Easy to forget - p. 254 22. 11.12 Alzheimer's disease and other neurodegenerative conditions - p. 256 23. 11.13 Target classes and key biological mechanisms - p. 259 24. 11.14 SARS-CoV-2 as case study in new and old technologies - p. 291 25. 11.15 Afterword - p. 291 26. References - p. 296 27. Chapter 12 Drug discovery processes: When and where the rubber meets the road - p. 339 28. Keywords - p. 339 29. 12.1 Introduction - p. 339 30. 12.2 Target identification and validation - p. 349 31. 12.3 Hit identification - p. 356 32. 12.4 Antibody-based drug discovery - p. 371 33. 12.5 Nucleic acid-based discovery - p. 378 34. 12.6 Hit-to-lead and lead optimization phases of drug discovery - p. 387 35. 12.7 Candidate selection - p. 400 36. 12.8 Afterword - p. 404 37. References - p. 404 38. Chapter 13 Drug discovery: Chaos can be your friend or your enemy - p. 417 39. Keywords - p. 417 40. 13.1 Introduction to selected aspects of biotechnology and pharmaceutical R&D - p. 417 41. 13.2 Major issues including attrition, cost, financing, ROI, and timelines - p. 434 42. 13.3 Champions, teams, and project management - p. 465 43. 13.4 Recruiting, developing, compensating, and retaining valuable human resources - p. 471 44. 13.5 Multiple sites and outsourcing - p. 476 45. 13.6 Comparing and contrasting centers and sectors of innovation - p. 479 46. 13.7 BD including IP - p. 484 47. 13.8 Afterword - p. 488 48. References - p. 491 49. Chapter 14 Research and discovery: Essential partners but just a start - p. 513 50. Chapter 15 Turning a potent agent—A chemical “drug”—into a registered product - p. 531 51. Chapter 16 Chemical development: Synthetic studies and engineering including aspects of batch production and continuous processing - p. 539 52. Chapter 17 Chemical development: Analytical studies - p. 553 53. Chapter 18 FDA path and process: Sponsor’s regulatory tasks for drug approval - p. 561 54. Chapter 19 Development of biological and other healthcare products - p. 575 55. Chapter 20 Epilogue - p. 619 56. Index - p. 633
